NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free RDHL Stock Alerts $0.54 +0.01 (+1.89%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.5450-Day Range$0.51▼$1.3252-Week Range$0.26▼$5.91Volume194,307 shsAverage Volume1.44 million shsMarket Capitalization$16.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get RedHill Biopharma alerts: Email Address Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About RedHill Biopharma Stock (NASDAQ:RDHL)RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More RDHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Stock News HeadlinesMarch 13, 2024 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Shares Pass Below 200-Day Moving Average of $0.80March 13, 2024 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Share Price Crosses Below Two Hundred Day Moving Average of $0.80March 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 11, 2024 | markets.businessinsider.comRedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaMarch 11, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Covering Talicia® Through 2034March 5, 2024 | finance.yahoo.comRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsFebruary 20, 2024 | finance.yahoo.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 20, 2024 | prnewswire.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: February 16, 2024 | barrons.comRedHill Biopharma Ltd. ADRJanuary 26, 2024 | finance.yahoo.comRedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingJanuary 25, 2024 | msn.comRedHill gains after new patent grant for Talicia for H. pylori treatment through 2042January 25, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042January 25, 2024 | finance.yahoo.comRedHill Biopharma Announces $8 Million Registered Direct OfferingJanuary 24, 2024 | benzinga.comWhy Redhill Biopharma Stock Is Moving HigherDecember 20, 2023 | msn.comRedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against EbolaDecember 20, 2023 | markets.businessinsider.comRedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus StudyDecember 20, 2023 | msn.comRedHill shares rally 20% on positive data for two antiviral drugsDecember 20, 2023 | finance.yahoo.comRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaDecember 12, 2023 | msn.comRedHill Biopharma regains compliance with Nasdaq listing ruleDecember 4, 2023 | finance.yahoo.comRedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 StudyNovember 30, 2023 | benzinga.comRedhill Biopharma Stock (NASDAQ:RDHL), Short Interest ReportNovember 29, 2023 | msn.comWhat's Going On With Redhill Biopharma Stock?November 27, 2023 | investorplace.com5 Investors Betting Big on RedHill Biopharma (RDHL) StockNovember 27, 2023 | msn.comWhy Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?November 27, 2023 | markets.businessinsider.comRedHill's Talicia Granted 5-year Market Exclusivity By FDANovember 27, 2023 | finance.yahoo.comRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034See More Headlines Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/30/2021Today3/19/2024Next Earnings (Estimated)4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees113Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,670,000.00 Net Margins354.95% Pretax MarginN/A Return on Equity-328.99% Return on Assets71.39% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.78 Sales & Book Value Annual Sales$61.80 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book Value($16.41) per share Price / Book-0.03Miscellaneous Outstanding Shares29,700,000Free Float27,680,000Market Cap$16.00 million OptionableNo Data Beta3.48 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Gilead Raday MPhil (Age 49)MSc, Chief Operating Officer Comp: $445.38kMr. Adi Frish (Age 54)Chief Corporate & Business Development Officer Comp: $419.5kMr. Razi Ingber (Age 40)Chief Financial Officer Ms. Alexandra OkmianSenior Business Development & Investor Relations ManagerDr. Reza Fathi Ph.D. (Age 69)Senior Vice President of Research & Development Comp: $299.29kMr. Guy Goldberg J.D. (Age 48)Chief Business Officer Comp: $338.13kDr. June S. Almenoff FACP (Age 67)M.D., Ph.D., Chief Medical Officer Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsMolecular TemplatesNASDAQ:MTEMAgeX TherapeuticsNYSE:AGEFortress BiotechNASDAQ:FBIOSynlogicNASDAQ:SYBXIndaptus TherapeuticsNASDAQ:INDPView All Competitors RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed in 2024? RedHill Biopharma's stock was trading at $1.46 at the beginning of 2024. Since then, RDHL shares have decreased by 63.1% and is now trading at $0.5386. View the best growth stocks for 2024 here. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) released its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($20.00) EPS for the quarter, missing analysts' consensus estimates of ($19.20) by $0.80. The biotechnology company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $23.41 million. RedHill Biopharma had a negative trailing twelve-month return on equity of 328.99% and a net margin of 354.95%. During the same quarter last year, the business earned ($20.00) earnings per share. When did RedHill Biopharma's stock split? RedHill Biopharma shares reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). Who are RedHill Biopharma's major shareholders? RedHill Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RDHL) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.